HighTower Advisors
CTXR icon

HighTower Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

HighTower Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,601
Closed -$107K – 3858
2024
Q3 		$107K Hold
8,601
– – ﹤0.01% 3298
2024
Q2 		$126K Buy
8,601
+207
+2% +$3.71K ﹤0.01% 3153
2024
Q1 		$188K Buy
8,394
+273
+3% +$4.99K ﹤0.01% 3005
2023
Q4 		$153K Sell
8,121
-247
-3% -$4.68K ﹤0.01% 3088
2023
Q3 		$143K Buy
8,368
+240
+3% +$5.7K ﹤0.01% 3018
2023
Q2 		$243K Sell
8,128
-240
-3% -$7.9K ﹤0.01% 2718
2023
Q1 		$244K Buy
8,368
+589
+8% +$17K ﹤0.01% 2604
2022
Q4 		$154K Buy
7,779
+954
+14% +$26K ﹤0.01% 2846
2022
Q3 		$206K Hold
6,825
– – ﹤0.01% 2586
2022
Q2 		$157K Sell
6,825
-1,880
-22% -$51.5K ﹤0.01% 2686
2022
Q1 		$389K Buy
8,705
+1,880
+28% +$74.3K ﹤0.01% 2344
2021
Q4 		$263K Hold
6,825
– – ﹤0.01% 2559
2021
Q3 		$347K Buy
6,825
+27
+0.4% +$1.35K ﹤0.01% 2319
2021
Q2 		$591K Hold
6,798
– – ﹤0.01% 1954
2021
Q1 		$303K Hold
6,798
– – ﹤0.01% 2292
2020
Q4 		$174K Buy
+6,798
New +$177K ﹤0.01% 2240

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

HighTower Advisors's CTXR Position: Q4 2024 in Review

HighTower Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 8,601 shares — an estimated $107K sold.

HighTower Advisors first reported a position in CTXR in Q4 2020 and held it in 16 quarters. The position peaked at $591K in Q2 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • HighTower Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • HighTower Advisors sold 8,601 Citius Pharmaceuticals shares in Q4 2024, an estimated $107K.
  • HighTower Advisors first reported a position in Citius Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • HighTower Advisors's Citius Pharmaceuticals position peaked at $591K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on HighTower Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.